Can-Fite BioPharma Ltd. – Product Pipeline Review – H2 2011

Document Sample
Can-Fite BioPharma Ltd. – Product Pipeline Review – H2 2011 Powered By Docstoc
					Can-Fite BioPharma Ltd. – Product Pipeline Review




  Can-Fite BioPharma Ltd. – Product Pipeline Review –
                       H2 2011


                                                                                          Reference Code: GMDHC02127CDB
                                                                                                 Publication Date: DEC 2011




Can-Fite BioPharma Ltd. – Product Pipeline Review – H2 2011                               GMDHC02127CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                               Page(1)
Can-Fite BioPharma Ltd. – Product Pipeline Review




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ................................................................................................................................................................................. 4
    List of Figures ................................................................................................................................................................................ 5
Can-Fite BioPharma Ltd. Snapshot .................................................................................................................................................... 6
    Can-Fite BioPharma Ltd. Overview ............................................................................................................................................... 6
    Key Information ............................................................................................................................................................................. 6
    Key Facts....................................................................................................................................................................................... 6
Can-Fite BioPharma Ltd. – Research and Development Overview .................................................................................................... 7
    Key Therapeutic Areas .................................................................................................................................................................. 7
Can-Fite BioPharma Ltd. – Pipeline Review....................................................................................................................................... 9
    Pipeline Products by Stage of Development ................................................................................................................................. 9
    Pipeline Products – Monotherapy ............................................................................................................................................... 10
Can-Fite BioPharma Ltd. – Pipeline Products Glance ...................................................................................................................... 11
    Can-Fite BioPharma Ltd. – Late Stage Pipeline .......................................................................................................................... 11
        Phase III Products/Combination Treatment Modalities ........................................................................................................... 11
    Can-Fite BioPharma Ltd. Clinical Stage Pipeline Products ......................................................................................................... 12
        Phase II Products/Combination Treatment Modalities ............................................................................................................ 12
    Can-Fite BioPharma Ltd. – Early Stage Pipeline Products .......................................................................................................... 13
        Pre-Clinical Products/Combination Treatment Modalities ....................................................................................................... 13
Can-Fite BioPharma Ltd. – Drug Profiles ......................................................................................................................................... 14
    CF101 .......................................................................................................................................................................................... 14
        Product Description................................................................................................................................................................. 14
        Mechanism of Action ............................................................................................................................................................... 14
        R&D Progress ......................................................................................................................................................................... 14
    CF102 .......................................................................................................................................................................................... 16
        Product Description................................................................................................................................................................. 16
        Mechanism of Action ............................................................................................................................................................... 16
        R&D Progress ......................................................................................................................................................................... 16
    CF502 .......................................................................................................................................................................................... 18
        Product Description................................................................................................................................................................. 18
        Mechanism of Action ............................................................................................................................................................... 18
        R&D Progress ......................................................................................................................................................................... 18
    CF602 .......................................................................................................................................................................................... 19
        Product Description................................................................................................................................................................. 19
        Mechanism of Action ............................................................................................................................................................... 19
        R&D Progress ......................................................................................................................................................................... 19
Can-Fite BioPharma Ltd. – Pipeline Analysis ................................................................................................................................... 20
    Can-Fite BioPharma Ltd. – Pipeline Products by Therapeutic Class ........................................................................................... 20
    Can-Fite BioPharma Ltd. - Pipeline Products By Target.............................................................................................................. 21
    Can-Fite BioPharma Ltd. – Pipeline Products by Route of Administration .................................................................................. 22
    Can-Fite BioPharma Ltd. – Pipeline Products by Molecule Type ................................................................................................ 23
Can-Fite BioPharma Ltd. – Recent Pipeline Updates ...................................................................................................................... 24



Can-Fite BioPharma Ltd. – Product Pipeline Review – H2 2011                                                                             GMDHC02127CDB / Published DEC 2011
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                       Page(2)
Can-Fite BioPharma Ltd. – Product Pipeline Review



Can-Fite BioPharma Ltd. - Dormant Projects ................................................................................................................................... 25
Can-Fite BioPharma Ltd. – Locations And Subsidiaries ................................................................................................................... 26
    Head Office.................................................................................................................................................................................. 26
    Other Locations & Subsidiaries ................................................................................................................................................... 26
Company's Recent Developments ................................................................................................................................................... 27
    Can-Fite BioPharma Ltd., Recent Developments ........................................................................................................................ 27
        May 31, 2009: Can-Fite BioPharma Completes Patient Enrollment For Phase II Trial In Psoriasis With CF101 .................... 27
        May 31, 2009: Can-Fite Completes Patient Enrollment For Phase II Trial In Psoriasis With CF101....................................... 27
        Mar 31, 2010: Can-Fite Reports Progress On Clinical Development Of CF102 Drug ............................................................. 28
        May 30, 2010: Can-Fite's CF102 Significantly Decreased Viral Load Of HCV In Liver Cancer Patient .................................. 28
        Apr 30, 2009: Can-Fite BioPharma's Phase IIb Study In Rheumatoid Arthritis Patients Fails Primary Efficacy Endpoint....... 29
        Apr 30, 2005: Can-Fite Announces To Initiate Clinical Studies To Test Efficacy Of CF101 In Treating Dry Eyes Syndrome . 29
        Sep 29, 2009: Can-Fite Initiates Preparatory Work For Psoriasis Phase III Trial With CF101 ................................................ 30
        Jul 26, 2010: Can-Fite's CF102 Significantly Decreases Viral Load Of HCV In Patients With Liver Cancer ........................... 30
        Sep 25, 2006: Can-Fite Out Licenses Rights For CF101 In Japan To The Seikagaku Corporation ....................................... 31
        Jul 23, 2003: Can-Fite BioPharma Commences Phase II Trial Of CF101 For The Treatment Of Active Rheumatoid Arthritis32
        May 23, 2010: Can-Fite BioPharma Receives Israeli MoH Approval To Conduct Phase II Clinical Trial Evaluating Efficacy Of
        CF101 In Patients With Glaucoma .......................................................................................................................................... 32
        Mar 22, 2010: Can-Fite BioPharma Announces Filing Of Patent Application In Conjunction With NIH To Treat Uveitis ........ 33
        May 17, 2009: Can-Fite BioPharma Announces Positive Results From Phase II Trial Treating Keratoconjunctivitis Sicca With
        CF101 ..................................................................................................................................................................................... 33
        Jul 16, 2007: Can-Fite Reports Results Of A Phase IIb Clinical Study In Rheumatoid Arthritis With CF101 .......................... 34
        Jul 14, 2009: Can-Fite BioPharma To Initiate Phase I/II Clinical Trial With CF102 For Treatment Of Hepatitis C Virus ......... 34
        Dec 13, 2009: Can-Fite BioPharma To Initiate Phase II Clinical Trial With CF101 For Treatment Of Glaucoma.................... 35
        Jun 13, 2007: Can-Fite Proceeds With Development Of Third Drug CF502 ........................................................................... 35
        May 11, 2011: Can-Fite Announces Promising Interim Analysis Data Of Phase I/II Liver Cancer Study With CF102 Drug ... 36
        Sep 10, 2006: Can-Fite Announces To Develop CF101 For Psoriasis, Among Other Indications .......................................... 37
        Sep 07, 2010: Can-Fite BioPharma Initiates Phase III Clinical Trial Of CF101 In Dry Eye Syndrome Patients ...................... 37
        Sep 07, 2009: Can-Fite BioPharma Announces Positive Results From Psoriasis Phase II Trial With CF101 ........................ 38
        Jun 07, 2010: Can-Fite BioPharma Announces Opening Of CF101 Dermatology IND With Phase II/III Psoriasis Protocol ... 38
        Nov 06, 2007: Can-Fite Announces That CF101 May Be Effective For The Treatment Of Crohn's Disease .......................... 39
        Nov 06, 2007: Can-Fite Announces That CF101 May Be Effective For The Treatment Of Crohn's Disease .......................... 39
        Jun 06, 2005: Can-Fite's CF101 Presents Positive Activity Data In Rheumatoid Arthritis Patients......................................... 40
        Sep 05, 2006: Can-Fite BioPharma Receives Israeli MoH Approval To Conduct A Clinical Trial Evaluating The Efficacy Of
        CF101 In Patients With Dry Eye Syndrome ............................................................................................................................ 40
        Aug 01, 2011: Can-Fite BioPharma Initiates Patient Enrollment For Phase II/III Psoriasis Study With CF101 ....................... 40
Financial Deals Landscape .............................................................................................................................................................. 41
    Can-Fite Bio
				
DOCUMENT INFO
Description: Can-Fite BioPharma Ltd. – Product Pipeline Review – H2 2011 Summary Global Market Direct’s pharmaceuticals report, “Can-Fite BioPharma Ltd. - Product Pipeline Review - H2 2011” provides data on the Can-Fite BioPharma Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Can-Fite BioPharma Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Can-Fite BioPharma Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team. Scope - Can-Fite BioPharma Ltd. - Brief Can-Fite BioPharma Ltd. overview including business description, key information and facts, and its locations and subsidiaries. - Review of current pipeline of Can-Fite BioPharma Ltd. human therapeutic division. - Overview of pipeline therapeutics across various therapy areas. - Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe. - Product profiles for late stage and clinical stage products of Can-Fite BioPharma Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Can-Fite BioPharma Ltd.’s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Can-Fite BioPharma Ltd.’s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Can-Fite BioPharma Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Can-Fite BioPharma Ltd.’s R&D portfolio and develop key strategic initiati
BUY THIS DOCUMENT NOW PRICE: $500 100% MONEY BACK GUARANTEED
PARTNER GlobalMarketsDirect
Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. Global Markets Direct has a broad range of coverage over key market segments. It has a global scope, covering a broad range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, Global Markets Direct employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries